Rapid Micro Biosystetms
Rapid Micro Biosystems helps companies in the pharmaceutical, biotech, and personal care products industries automate and accelerate their microbial quality control testing, often a gating factor to product release.
With offices in the US and Europe, Rapid Micro Biosystems has a singular focus on providing businesses a technology for automated rapid detection through the Growth Direct™ System.
The Growth Direct™ System, by Rapid Micro Biosystems, automates the detection and enumeration of colonies in microbial quality control in manufacturing. The system includes 2 incubators, robotics and imaging systems that detect and enumerate microbial growth in about half the time of the traditional method. By using the natural autoflouresence of living cells, the system “sees” colonies forming at about 100 cells, far sooner than the human eye. This allows the technology to provide results in about half the time of the traditional method while preserving the colony.
The Growth Direct™ System is designed to be a single test method for use with all the key tests in the microbial quality control lab including bioburden testing, environmental monitoring and sterility testing. Sample preparation closely matches the existing tests, simplifying training of technicians. The technology can support all tests within one instrument, or each test within a separate unit.
Contact Details:
Company Name: Rapid Micro Biosystems
Address: One Oak Park Drive, Bedford, MA (USA)
Tel: +1 781 271 1444
Fax: +1 781 271 9905
Web: www.rapidmicrobio.com
Contact: Mark Severns
Email: sales@rapidmicrobio.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
